Diabetes, Metabolic Syndrome and Obesity (Jun 2022)

Fibrosis Predictive Score in Caucasian Patients with Metabolic Syndrome

  • Mare R,
  • Sporea I,
  • Tomescu M,
  • Pop GN,
  • Vitel A,
  • Popescu A,
  • Nistorescu S,
  • Sirli R

Journal volume & issue
Vol. Volume 15
pp. 1703 – 1713

Abstract

Read online

Ruxandra Mare,1,2 Ioan Sporea,1,2 Mirela Tomescu,3 Gheorghe Nicușor Pop,3 Andrei Vitel,3 Alina Popescu,1,2 Silviu Nistorescu,1 Roxana Sirli1,2 1Department of Internal Medicine II, Gastroenterology and Hepatology Unit, Advanced Research Center in Gastroenterology and Hepatology “Victor Babes” University of Medicine and Pharmacy, Timisoara, Romania; 2Regional Center of Research in Advanced Hepatology, Academy of Medical Science, Timisoara, Romania; 3Department VI of Cardiology, “Victor Babeș” University of Medicine and Pharmacy, Timisoara, RomaniaCorrespondence: Roxana Sirli, Department of Internal Medicine II, Gastroenterology and Hepatology Unit, Advanced Research Center in Gastroenterology and Hepatology “Victor Babes” University of Medicine and Pharmacy, Timisoara, Romania, Tel +40723537039, Fax +40723537039, Email [email protected]: Many of the patients presenting with metabolic syndrome (MetS) also have liver steatosis (NAFLD) and some of them could develop liver fibrosis.Purpose: To develop a simple score that could rule out fibrosis, especially significant fibrosis (F≥ 2) and could be used in daily practice in patients with MetS, in order to identify patients at risk.Patients and Methods: A total of 204 patients with MetS were prospectively enrolled. Evaluation of liver fibrosis was made using Vibration Controlled Transient Elastography while evaluation of steatosis was achieved using ultrasound (US).Results: Out of 204 patients with MetS, 179 patients (87.7%) had reliable liver stiffness measurements and 22.9% (41/179) had F ≥ 2. To formulate the fibrosis predicting score, all clinical variables associated with F ≥ 2 in the univariate analysis were considered in a multivariate regression model. According to the power of correlation, by consensus, we attributed 1 point for BMI > 31.4 kg/m2, 1 point for female gender, 1 point for HDLc < 47mg/dL, 1 point for mild steatosis at US, 1.5 point for moderate and 2 points for severe steatosis.Conclusion: At an optimal cut-off value of < 3.5, our score could be used to rule-out the risk for developing at least significant fibrosis with a high negative predictive value (NPV 89.2%) in patients with MetS.Keywords: metabolic syndrome, liver steatosis, liver fibrosis, liver elastography

Keywords